Adherence and persistence in patients with severe osteoporosis treated with teriparatide

References

• Borgstrom F, Zethraeus N, Johnell O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 2006;175:637-50
   Google Scholar
• Kanis JA, Oden A, Johnell O, et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004;152:108-12
   Google Scholar
• Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;1512:1003-8
   Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;818:1013-22
   Google Scholar
• Silverman SL, Gold DT, Cramer JA. Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies. South Med J 2007;10012:1214-18
   Google Scholar
• Curtis JR, Westfall AO, Cheng H, et al. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 2008;239:1435-41
   Google Scholar
• Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009;1222(Suppl.):S3-13
   Google Scholar
• Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997;13811:4607-12
   Google Scholar
• Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine 2008;753:303-10
   Google Scholar
• Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;188:1023-31
   Google Scholar
• McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;483:271-87
   Google Scholar
• Bartl R, Gotte S, Hadji P, et al. [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment]. Dtsch Med Wochenschr 2006;13122:1257-62
   Google Scholar
• Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;176:914-21
   Google Scholar
• Haynes RB, Montague P, Oliver T, et al. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2000;2:CD000011
   Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;34419:1434-41
   Google Scholar
• Gallagher JC, Genant HK, Crans GG, et al. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 2005;903:1583-7
   Google Scholar
• Hess. Arzneimittelrichtlinie AMR/Therapiehinweis Teriparatid. Deutsches Ärzteblatt 2007;104:1043-48
   Google Scholar
• Ziller V, Kalder M, Albert US, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009;203:431-6
   Google Scholar
• WHO. Adherence Project. WHO Publications, 2003
   Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;111:44-7
   Google Scholar
• Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;241:67-74
   Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;219:1453-60
   Google Scholar
• Ziller V, Ossendorf A, Funk E, et al. Compliance in der Therapie der Osteoporose mit wöchentlicher Bisphosphonatgabe – Analyse einer Zufallsstichprobe aus der klinischen Praxis. Osteologie 2007;16(Suppl. 1):5-10
   Google Scholar
• Ziller V, Wetzel K, Hadji P. Adherence and Persistence in Patients with Postmenopausal Osteoporosis Treated with Raloxifene. J Bone Miner Res Annual Meeting Abstract, 2009
   Google Scholar
• Arden NK, Earl S, Fisher DJ, et al. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int 2006;1711:1626-9
   Google Scholar
• Briot K, Ravaud P, Argent-Molina P, et al. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int 2008;20:625-30
   Google Scholar
• Lincoln TM, Wilhelm K, Nestoriuc Y. Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. Schizophr Res 2007;961-3:232-45
   Google Scholar
• Ziller V, Zimmermann S-P, Hadji P. Adherence in Patients with Severe Osteoporosis Treated with Teriparatide. J Bone Miner Res, Annual meeting abstract 2008;Poster M384
   Google Scholar